Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.

Clarithromycin, a macrolide antibiotic, is defined as a group 5 anti-tuberculosis drug by the World Health Organization; however, its role or efficacy in the treatment of MDR-TB is unclear. A systematic review of the literature was conducted to summarise the evidence for the activity of macrolides against MDR-TB, by evaluating in vitro, in vivo and clinical studies. Even though high minimum inhibitory concentration values are usually found, suggesting low activity against Mycobacterium tuberculosis, the potential benefits of macrolides are their accumulation in the relevant compartments and cells in the lungs, their immunomodulatory effects and their synergistic activity with other anti-TB drugs.
Source : www.ncbi.nlm.nih.gov      2015/9/26 09:13

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.